Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians

被引：15

作者：

Dittmann R.W. ^{[1
]}

Wehmeier P.M. ^{[2
]}

Schacht A. ^{[2
]}

Minarzyk A. ^{[2
]}

Lehmann M. ^{[2
]}

Sevecke K. ^{[3
]}

Lehmkuhl G. ^{[3
]}

机构：

[1] Department of Child and Adolescent Psychiatry, Central Institute of Mental Health Mannheim, University of Heidelberg

[2] Lilly Deutschland GmbH, Medical Department, Bad Homburg

[3] Department of Child and Adolescent Psychiatry, University of Cologne

来源：

Child and Adolescent Psychiatry and Mental Health | / 3卷 / 1期

关键词：

ADHD Symptom; Atomoxetine; Oppositional Defiant Disorder; Last Observation Carry Forward; Combine Subtype;

D O I：

10.1186/1753-2000-3-21

中图分类号：

学科分类号：

摘要：

Background: The degree of ADHD-related difficulties - reflecting overall impairment, social functioning, and quality of life - may be perceived differently by adolescent patients, parents and physicians. The primary aim of this study was to investigate ADHD-related difficulties during atomoxetine treatment, as perceived by the three different raters. Secondary objectives focused on effectiveness and tolerability of atomoxetine treatment in a population of adolescent patients with ADHD. Methods: Adolescents with ADHD, aged 12-17 years, received open-label atomoxetine (0.5-1.2 mg/kg/day) up to 24 weeks. ADHD-related difficulties at various times of the day were rated using the Global Impression of Perceived Difficulties (GIPD) instrument. Inter-rater agreement was analyzed using Cohen's Kappa with 95% confidence intervals (95% CI). ADHD-Rating Scale (ADHD-RS) and Clinical Global Impression Severity (GGI-S) scores were assessed by the investigator; and spontaneous adverse events, vital signs and laboratory parameters were collected for tolerability assessments. Results: 159 patients received atomoxetine. Patients' baseline mean GIPD total ratings were significantly lower than parents' and physicians' scores (12.5 [95%CI 11.6;13.5] vs. 17.2 [16.2;18.2] and 18.8 [17.8;19.8]). For all raters, GIPD scores significantly improved over time. Changes were greatest within the first two weeks. Kappa coefficients varied between 0.186 [0.112;0.259] and 0.662 [0.529;0.795], with strongest agreements between parent and physician assessments, and significant improvements of patient/physician agreements over time (based on 95% CIs). ADHD-RS and CGI-S scores significantly improved over the course of the study (based on 95% CIs). Tolerability results were consistent with earlier reports. Conclusion: ADHD-related difficulties were perceived differently by the raters in this open-label trial, but consistently improved during atomoxetine treatment. The GIPD instrument appeared sensitive to treatment-related change. These primarily quantitative findings may guide future studies to more systematically investigate the clinical and practical relevance of the differences observed. Additionally, in order to further validate these results, placebo- and comparator-controlled trials are recommended as well as inclusion of healthy controls and other patient populations. Trial Registration: Clinical Trial Registry: ClinicalTrials.gov: NCT00191737. © 2009 Dittmann et al; licensee BioMed Central Ltd.

引用

共 50 条

[21]

DuPaul G.J., Power T.J., Anastopoulos A.D., Reid R., ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations, pp. 28-42, (1998)

[22]

Faries D.E., Yalcin I., Harder D., Heiligenstein J.H., Validation of the ADHD Rating Scale as a clinician administered and scored instrument, J Atten Disord, 5, pp. 39-47, (2001)

[23]

Guy W., ECDEU Assessment Manual for Psychopharmacology, 338, pp. 534-537, (1976)

[24]

Rating scales and assessment instruments for use in pediatric psychopharmacology research., Psychopharmacology Bull, 21, 4, pp. 714-1124, (1985)

[25]

Landgraf J., Abetz L., Ware J., Child Health Questionnaire (CHQ): A Users Manual, (1996)

[26]

Riley A.W., Forrest C.B., Starfield B., Rebok G.W., Robertson J.A., Green B.F., The Parent Report Form of the CHIP-Child Edition: Reliability and Validity, Medical Care, 42, pp. 210-220, (2004)

[27]

Brown R.T., Perwien A., Faries D.E., Kratochvil C.J., Vaughan B.S., Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning, Clin Pediatrics (Phila), 45, pp. 819-827, (2006)

[28]

Buitelaar J.K., Danckaerts M., Gillberg C., Zuddas A., Becker K., Bouvard M., Fagan J., Gadoros J., Harpin V., Hazell P., Johnson M., Lerman-Sagie T., Soutullo C.A., Wolanczyk T., Zeiner P., Fouche D.S., Krikke-Workel J., Zhang S., Michelson D., A prospective, multi-center, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD, Eur Child Adolesc Psychiatry, 13, pp. 249-257, (2004)

[29]

Perwien A.R., Faries D.E., Kratochvil C.J., Sumner C.R., Kelsey D.K., Allen A.J., Improvement in health-related quality of life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine, J Dev Behav Pediatr, 25, pp. 264-271, (2004)

[30]

Perwien A.R., Kratochvil C.J., Faries D.E., Vaughan B.S., Spencer T., Brown R.T., Atomoxetine Treatment in Children and Adolescents with Attention-Deficit Hyperactivity Disorder: What Are the Long-Term Health-Related Quality-of-Life Outcomes?, J Child Adolesc Psychopharmacol, 16, pp. 713-724, (2006)

← 1 2 3 4 5 →